Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
/in Dendritic Cells, Hypernephroma, International Publications, Malignant MelanomaAntigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model
/in Dendritic Cells, International Publications, Pancreatic CancerClinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis
/in Dendritic Cells, Glioblastoma, International PublicationsMultimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusRetrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International PublicationsEfficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route
/in Dendritic Cells, International Publications, Malignant MelanomaImproved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
/in Dendritic Cells, Exosome, Glioblastoma, Hypernephroma, International PublicationsThe effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
/in Dendritic Cells, Hyperthermia, International PublicationsA phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
/in Dendritic Cells, Hypernephroma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer